The V2 loop of HIV gp120 delivers costimulatory signals to CD4<sup>+</sup> T cells through Integrin α<sub>4</sub>β<sub>7</sub> and promotes cellular activation and infection.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33288704.
- Also identified by DOI 10.1073/pnas.2011501117 and PMC identifier 7768698.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Acute HIV infection is characterized by rapid viral seeding of immunologic inductive sites in the gut followed by the severe depletion of gut CD4<sup>+</sup> T cells. Trafficking of α<sub>4</sub>β<sub>7</sub>-expressing lymphocytes to the gut is mediated by MAdCAM, the natural ligand of α<sub>4</sub>β<sub>7</sub> that is expressed on gut endothelial cells. MAdCAM signaling through α<sub>4</sub>β<sub>7</sub> costimulates CD4<sup>+</sup> T cells and promotes HIV replication. Similar to MAdCAM, the V2 domain of the gp120 HIV envelope protein binds to α<sub>4</sub>β<sub>7</sub> In this study, we report that gp120 V2 shares with MAdCAM the capacity to signal through α<sub>4</sub>β<sub>7</sub> resulting in CD4<sup>+</sup> T cell activation and proliferation. As with MAdCAM-mediated costimulation, cellular activation induced by gp120 V2 is inhibited by anti-α<sub>4</sub>β<sub>7</sub> monoclonal antibodies (mAbs). It is also inhibited by anti-V2 domain antibodies including nonneutralizing mAbs that recognize an epitope in V2 that has been linked to reduced risk of acquisition in the RV144 vaccine trial. The capacity of the V2 domain of gp120 to mediate signaling through α<sub>4</sub>β<sub>7</sub> likely impacts early events in HIV infection. The capacity of nonneutralizing V2 antibodies to block this activity reveals a previously unrecognized mechanism whereby such antibodies might impact HIV transmission and pathogenesis.
Medical subject headings
- CD4-Positive T-Lymphocytes
- HIV Envelope Protein gp120
- HIV Infections
- Integrins